story of the week
Atezolizumab Plus Nab-Paclitaxel as First-Line Treatment for Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Atezolizumab Plus Nab-Paclitaxel as First-Line Treatment for Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer (IMpassion130): Updated Efficacy Results From a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial
Lancet Oncol 2019 Nov 27;[EPub Ahead of Print], P Schmid, HS Rugo, S Adams, A Schneeweiss, CH Barrios, H Iwata, V Diéras, V Henschel, L Molinero, SY Chui, V Maiya, A Husain, EP Winer, S Loi, LA EmensFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.